Navigation Links
Visikol to Present Three Talks at SLAS Highlighting 3D Cell Culture Assay Services
Date:1/30/2019

The Society for Laboratory Automation and Screening conference brings together experts from pharma, academia and governmental agencies to discuss best practices for laboratory automation and screening. This year the conference will be held in Washington, DC from February 4-6.

At this year’s conference, Visikol will be at booth #345 and throughout the conference will highlight its unique service offering through a suite of talks and poster sessions. Visikol was originally founded to commercialize novel imaging technologies and has since evolved into a leading contract research organization in the fields of advanced imaging, 3D cell culture assays and digital pathology. At SLAS, Visikol will specifically focus on showcasing its 3D cell culture services which have become very popular in the last few years as researchers shift their efforts to in vitro models with improved in vivo relevancy.

“We are excited by the growth of this space and see ourselves as having the most comprehensive offering of 3D cell culture assays in the market as we can provide simple and routine assay end-points as well as the highest quality 3D imaging and analysis endpoints possible through the use of our patented Visikol® HISTO-M™ technology and proprietary image analysis tools,” described Visikol CEO Dr. Michael Johnson. In this field, Visikol has taken a unique approach to partnering with Client’s wherein they have adopted an application specific approach such that each research question is paired with a specific type of model and assay end-point. “We see our application specific approach to 3D cell culture assays as essential in minimizing cost while maximizing throughput and ensuring that a model has an appropriate degree of in vivo relevancy,” explains Visikol CSO Dr. Tom Villani.

At SLAS, the Visikol team will discuss its 3D cell culture assay services and will describe in detail its immune cell infiltration assay as well as its antibody penetration assay through separate talks. In addition to these talks, Visikol’s Director of In Vitro Studies, Dr. Erin Edwards will discuss Visikol’s OpenLiver™ initiative for developing open source liver 3D cell culture models. For the details on all three of the talks see below or pickup more info at the Visikol booth.

  • Visikol Solutions Spotlight: High Content 3D Cell Culture Immune Cell Infiltration Assessment: Many pharmaceutical companies are now focused on turning the immune system against cancer and developing novel immune-oncology therapeutics. In 2018, a major area of focus for Visikol was assisting pharmaceutical companies in developing 3D cell culture in vitro systems for quantifying immune cell infiltration into solid tumor models. This session highlighting immuno oncology in vitro assays will be on 2/4/19 from 3:30 – 3:50 pm in the exhibitor theatre and will be hosted by Visikol’s Chief Science Officer Dr. Tom Villani.
  • Visikol Solutions Spotlight: Building Consensus in the Liver 3D Cell Culture Model Space Through Open Source Models: While Visikol works with many Clients to develop novel cancer 3D cell culture models, most researchers assessing drug induced liver injury (DILI) and other liver pathologies are interested in standardized and validated models. To help address this need, Visikol has launched its OpenLiver™ initiative which is aimed at providing researchers with standardized open source models for specific research questions in order to optimize cost, complexity, validation and throughput. This session highlighting liver 3D cell culture models will be on 2/5/19 10:30 – 10:50 am in the exhibitor theatre and will be hosted by Visikol’s Director of In Vitro Studies Dr. Erin Edwards.
  • Podium Presentation: High Throughput Measurement of Antibody Drug Pharmacokinetics Using 3D Cell Culture Models. This session will take place on 2/5/2019 from 11:00 – 11:30 am and will be presented by Visikol’s Chief Science Officer Dr. Tom Villani.

About Visikol
Visikol is a CRO focused on advanced drug discovery that is leading the field of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Read the full story at https://www.prweb.com/releases/visikol_to_present_three_talks_at_slas_highlighting_3d_cell_culture_assay_services/prweb16054196.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Visikol CEO Dr. Michael Johnson Named to 2019 Forbes 30 Under 30 List as a Top Three All Star Alumni
2. Visikol Machine Learning Digital Pathology Services for Drug Discovery
3. Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak with Governor Murphy on Behalf of the Science, Innovation, and Technology Commission Bill
4. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
5. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
6. VetStem Biopharma CEO, Dr. Robert Harman, will Present Data on Stem Cells for Kidney Disease in Poster Session at Feline Veterinary Conference
7. CEO of VetStem Biopharma, Dr. Robert Harman, to Present Results of Safety Study for Allogeneic Stem Cell Product at Regenerative Medicine Conference
8. USDM Life Sciences’ Manu Vohra to Present on Box GxP at BoxWorks 2018 in San Francisco
9. BRAG Requests that EPA Adopt TSCA Inventory Representation and Equivalency For Renewable and Sustainable Biobased Chemicals
10. Subbu Viswanathan and Jennifer Jaye to Present at BoxWorks in San Francisco
11. Tunnell Consulting’s Julia O’Neill Presents at Fall Technical Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 09, 2019 , ... ... trial randomization and drug supply chain management, today announced its new technology partnership ... sciences industry. , “The integration between Veeva Vault EDC and our IRT will ...
(Date:9/9/2019)... ... 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave a ... to characterize 3D cell culture models. The inherent problem of characterizing 3D cell culture ... to image through and therefore traditional wide-field or even confocal microscopy only tells you ...
(Date:9/4/2019)... (PRWEB) , ... September 03, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... Director, Science & Technology will present at the upcoming Nordic Life Science ...
(Date:8/29/2019)... Kan. (PRWEB) , ... August 28, 2019 , ... ... expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International Baking ... to solve today’s baking challenges from optimizing production efficiency to cost and waste ...
Breaking Biology Technology:
(Date:8/14/2019)... ... , ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests ... annual Inc. 500|5000 list of fastest growing private companies, in the first year ... and generating revenue by March 31, 2015. Ranking in the list is determined by ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
(Date:8/6/2019)... , ... August 06, 2019 , ... ... a computational modeling system that could have far-reaching implications for personalized medicine, especially ... squares regression (PLSR), is able to predict which stem cell donors and manipulation ...
Breaking Biology News(10 mins):